J Diabetes Invest2014; 5: 570--580

Introduction {#jdi12181-sec-0005}
============

Type 2 diabetes is a progressive disease, and pancreatic β‐cell function might have a crucial role during the course of its progression[1](#jdi12181-bib-0001 jdi12181-bib-0002){ref-type="ref"}. Indeed, the results of the United Kingdom Progressive Disease Study showed that a deterioration in glycemic control observed over time was related to the decline in β‐cell function, as assessed using modelized plasma insulin/glucose (homeostasis model assessment of β‐cell function \[HOMA‐β\]) in patients treated with diet alone or oral hypoglycemic agents (OHA)[3](#jdi12181-bib-0003){ref-type="ref"}. Therefore, the accurate evaluation of residual pancreatic β‐cell function is important for deciding whether insulin treatment is required to control type 2 diabetes. In addition to well‐known β‐cell function‐related parameters, such as HOMA‐β, the serum C‐peptide itself, the serum C‐peptide response to glucagon and the 24‐h urinary C‐peptide (U‐CPR) level[4](#jdi12181-bib-0004 jdi12181-bib-0005 jdi12181-bib-0006 jdi12181-bib-0007){ref-type="ref"}, recent reports have shown that the fasting serum C‐peptide immunoreactivity (CPR) adjusted according to the fasting plasma glucose (FPG) level, such as the CPR index (CPI) and the secretory units of islets in transplantation index (SUIT; developed using the fasting CPR \[F‐CPR\] and the FPG level after islet transplantation), might be useful for evaluating residual pancreatic β‐cell function[8](#jdi12181-bib-0008 jdi12181-bib-0009 jdi12181-bib-0010){ref-type="ref"}. Furthermore, several reports have examined the correlation between these β‐cell function‐related parameters and the choice of insulin therapy to achieve glycemic control[9](#jdi12181-bib-0009 jdi12181-bib-0010 jdi12181-bib-0011 jdi12181-bib-0012 jdi12181-bib-0013 jdi12181-bib-0014 jdi12181-bib-0015 jdi12181-bib-0016){ref-type="ref"}. However, to the best of our knowledge, no reports have comprehensively compared the abilities of C‐peptide‐based indices, such as CPI, SUIT and U‐CPR, and a serum insulin‐based index, such as HOMA‐β (which is widely used for assessing the insulin secretory capacity) to predict insulin therapy requirement. Furthermore, as the CPI and SUIT were only recently identified as indices of β‐cell function, the relationship between CPI or SUIT and HOMA‐β is not fully understood.

With the aforementioned background in mind, we carried out a cross‐sectional study to determine the relationship among the β‐cell function‐related parameters. Then, in a retrospective case--controlled study, we further examined the cut‐off values and the utility of β‐cell function‐related parameters for the prediction of insulin requirement in patients with type 2 diabetes.

Materials and Methods {#jdi12181-sec-0006}
=====================

Participants {#jdi12181-sec-0007}
------------

A total of 442 Japanese patients with type 2 diabetes admitted between October 2006 and April 2011 to the University of Toyama Hospital (Toyama, Japan) for the management of hyperglycemia were selected in the present study. Type 2 diabetes mellitus was diagnosed based on the criteria of the American Diabetes Association (ADA)[17](#jdi12181-bib-0017){ref-type="ref"}. Among these patients, to compare the abilities of the HOMA‐β and the other β‐cell function‐related parameters to predict insulin requirement, we excluded patients who were already undergoing insulin therapy at the time of admission. In addition, we excluded: (i) patients with a serum creatinine level of 1.5 mg/dL or more; (ii) patients with hepatic dysfunction or malignant disease or who were taking steroids; (iii) patients who could not be clinically followed for at least 12 months; and (iv) patients with a glycosylated hemoglobin A1c (HbA1c) level \>7.0% despite the use of OHA or patients who received insulin, but at a dosage \<10 U/day at 12 months after discharge. Finally, 188 inpatients (see Table [1](#jdi12181-tbl-0001){ref-type="table-wrap"}) who received a follow‐up examination at least 12 months after discharge were enrolled in the present study.

###### Comparison of clinical characteristics between non‐insulin‐requiring group and insulin‐requiring group

                                                                    Total           Non‐insulin‐requiring group   Insulin‐ requiring group   *P* values   *P*‐values\* Multivariate
  ----------------------------------------------------------------- --------------- ----------------------------- -------------------------- ------------ ---------------------------
  Clinical characteristics at admission                                                                                                                   
  Age (years)                                                       61.0 ± 12.6     61.6 ± 13.5                   60.3 ± 11.1                0.262        
  *n* (Male/female)                                                 188 (126/62)    112 (75/37)                   76 (51/25)                 0.984        
  BMI (kg/m^2^)                                                     24.6 ± 4.8      25.3 ± 5.0                    23.6 ± 4.4                 \<0.05       
  Waist circumference (cm)                                          88.6 ± 8.7      90.2 ± 8.4                    86.9 ± 8.9                 0.052        
  Duration of diabetes (years)                                      8.4 ± 7.8       7.0 ± 7.3                     10.5 ± 8.1                 \<0.01       
  Family history of diabetes (%)                                    51.3            45                            60.5                       \<0.05       
  FPG (mg/dL)                                                       176.1 ± 71.1    148.4 ± 51.4                  216.5 ± 76.7               \<0.001      
  HbA1c (%)                                                         9.3 ± 2.3       8.6 ± 2.3                     10.3 ± 2.0                 \<0.001      
  eGFR (mL/min)                                                     85.4 ± 26.9     84.2 ± 23.7                   87.2 ± 30.3                0.514        
  Diabetes therapy before admission                                                                                                                       
  Untreated                                                         32.4            35.7                          27.6                       0.245        
  Diet alone (%)                                                    11.2            15.2                          5.2                        \<0.05       
  Use of oral hypoglycemic agents (%)                               56.4            47.3                          67.1                       \<0.01       
  Sulfonylureas (%)                                                 43.6            35.7                          55.3                       \<0.01       
  Thiazolidinediones (%)                                            13.8            12.5                          15.8                       0.521        
  Biguanides (%)                                                    16.0            10.7                          23.7                       \<0.01       
  α‐Glucosidase inhibitor (%)                                       22.9            12.5                          36.8                       \<0.001      
  Glinide (%)                                                       2.7             1.8                           3.9                        0.366        
  DPP‐4 inhibitor (%)                                               1.6             1.8                           1.3                        0.801        
  Complications                                                                                                                                           
  Diabetic retinopathy (%)                                          30.6            19.6                          46.1                       \<0.001      
  Diabetic nephropathy (%)                                          30              29.9                          30.3                       0.509        
  Diabetic neuropathy (%)                                           40.9            33.7                          51.4                       \<0.05       
  β‐Cell function‐related indices                                                                                                                         
  F‐CPR (ng/mL)                                                     2.17 ± 0.97     2.28 ± 0.83                   2.00 ± 1.14                \<0.01       0.255
  CPI                                                               1.43 ± 0.88     1.70 ± 0.87                   1.03 ± 0.73                \<0.001      \<0.001
  SUIT                                                              45.2 ± 65.7     60.3 ± 80.9                   23.9 ± 19.6                \<0.001      \<0.001
  F‐IRI                                                             6.65 ± 4.67     7.28 ± 4.73                   5.61 ± 4.42                \<0.01       0.223
  HOMA‐IR                                                           2.64 ± 2.03     2.68 ± 2.10                   2.70 ± 1.86                0.861        0.842
  HOMA‐β (%)                                                        34.6 ± 55.8     44.7 ± 67.4                   18.2 ± 20.3                \<0.001      \<0.01
  HOMA‐S%                                                           158.6 ± 136.2   142.6 ± 116.2                 185.1 ± 161.8              0.097        0.073
  HOMA‐B%                                                           34.8 ± 32.1     43.6 ± 35.3                   20.0 ± 18.3                \<0.001      \<0.001
  U‐CPR (μg/day)                                                    52.7 ± 42.4     57.6 ± 42.6                   45.8 ± 41.4                \<0.05       0.723
  U‐CPR index                                                       0.37 ± 0.35     0.44 ± 0.39                   0.27 ± 0.25                \<0.001      0.217
  Diabetes therapy at discharge                                                                                                                           
  Diet alone (%)                                                    19.7            32.1                          1.3                        \<0.001      
  Sulfonylureas (%)                                                 25.5            32.1                          15.8                       \<0.05       
  Thiazolidinediones (%)                                            6.9             7.1                           6.6                        0.881        
  Biguanides (%)                                                    12.2            14.3                          9.2                        0.297        
  α‐Glucosidase inhibitor (%)                                       21.9            19.6                          25.0                       0.383        
  Glinide (%)                                                       1.6             2.7                           0                          0.150        
  DPP‐4 inhibitor (%)                                               5.3             8.0                           1.3                        \<0.05       
  Insulin therapy (%)                                               47.8            15.2                          96.1                       \<0.001      
  Insulin (U/kg/day)                                                0.32 ± 0.19     0.25 ± 0.05                   0.35 ± 0.19                \<0.05       
  Glycemic control and diabetes therapy at 1 year after discharge                                                                                         
  HbA1c (%)                                                         7.15 ± 1.34     6.66 ± 0.32                   7.88 ± 1.50                \<0.001      
  Diabetes therapy                                                                                                                                        
  Diet alone (%)                                                    18.6            31.3                          0                          \<0.001      
  Sulfonylureas (%)                                                 26.1            34.8                          13.2                       \<0.001      
  Thiazolidinediones (%)                                            9.0             11.6                          5.3                        0.137        
  Biguanides (%)                                                    13.8            17.0                          9.2                        0.131        
  α‐Glucosidase inhibitor (%)                                       26.6            24.1                          30.2                       0.349        
  Glinide (%)                                                       2.7             2.7                           2.6                        0.984        
  DPP‐4 inhibitor (%)                                               5.3             8.9                           0                          \<0.01       
  Insulin (U/kg/day)                                                --              --                            0.32 ± 0.18                             

Data are the mean ± standard deviation. Between the non‐insulin‐requiring group and the insulin‐requiring group, the *P*‐values were calculated using a Mann--Whitney *U*‐test for differences between means, and a χ^2^‐test for differences between frequencies. Between the non‐insulin‐requiring group and the insulin‐requiring group, the multivariate *P*‐values\* were adjusted for age, sex, glycosylated hemoglobin A1c (HbA1c), body mass index (BMI), estimated glomerular filtration rate (eGFR), intake of insulin secretagogue, intake of α‐glucosidase inhibitor, intake of biguanides and duration of diabetes. CPI, C‐peptide index; DPP‐4, dipeptidyl peptidase 4; F‐CPR, fasting serum C‐peptide immunoreactivity; F‐IRI, fasting immunoreactive insulin; FPG, fasting plasma glucose; HOMA‐β, homeostasis model assessment of β‐cell function; HOMA‐B, homeostasis model assessment of insulin secretion using the HOMA2 calculator; HOMA‐IR, homeostasis model assessment of insulin resistance; HOMA‐S, homeostasis model assessment of insulin sensitivity using the HOMA2 calculator; SUIT, secretory units of islets in transplantation index; U‐CPR, 24‐h urinary C‐peptide; U‐CPR index, 24‐h urinary C‐peptide/fasting plasma glucose.
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Measurements {#jdi12181-sec-0008}
------------

All the measurements were carried out by the Department of Laboratory Medicine, University of Toyama Hospital, Toyama, Japan, using routine automated laboratory methods. The HbAlc level was measured using high‐performance liquid chromatography and was expressed as the international standard value; that is, HbA1c (Japan Diabetes Society \[JDS\]) + 0.4%, as defined by the JDS[18](#jdi12181-bib-0018 jdi12181-bib-0019){ref-type="ref"}. The serum C‐peptide level was measured using an electrochemiluminescence immunoassay (C‐peptide Kit^®^; Roche Diagnostics, Tokyo, Japan). The serum insulin level was measured using a chemiluminescent enzyme immunoassay (Insulin Kit^®^; Roche Diagnostics).

We measured the FPG, F‐CPR, fasting immunoreactive insulin (F‐IRI), urinary C‐peptide and urinary creatinine levels in the inpatients after overnight fasting on the second or third hospital day, and then calculated the CPI, HOMA‐β, HOMA of insulin resistance (IR), and urinary‐CPR index (U‐CPR index). The CPI and SUIT were calculated as follows[10](#jdi12181-bib-0010 jdi12181-bib-0014){ref-type="ref"}: F‐CPR (ng/mL) / FPG (mg/dL) × 100, and 1,500 × F‐CPR (ng/mL) / (FPG -- 61.7), respectively. In addition, the 24‐h urinary CPR (U‐CPR) was also measured. The U‐CPR index was calculated as the U‐CPR (μg/day) / FPG (mg/dL), as previously reported[10](#jdi12181-bib-0010 jdi12181-bib-0013){ref-type="ref"}. The HOMA‐β and HOMA‐IR were calculated as previously reported[7](#jdi12181-bib-0007){ref-type="ref"}. Furthermore, we also calculated the HOMA of insulin secretion and HOMA of insulin sensitivity using HOMA2 calculator (<http://www.dtu.ox.ac.uk/homacalculator/>).

Diabetic complications were precisely evaluated during admission. The diagnosis of diabetic retinopathy was carried out by an ophthalmologist.

All the study procedures were approved by the ethics committee of the University of Toyama. Informed consent was obtained from each participant, and anonymity of the participants was preserved during the study.

Treatment Policy and Classification of the Participants {#jdi12181-sec-0009}
-------------------------------------------------------

The treatment policy and classification of participants is shown in Figure [1](#jdi12181-fig-0001){ref-type="fig"}. Lifestyle modification including dietary therapy with an ideal caloric intake calculated from the ideal bodyweight (kg) × 25--30 kcal/kg and exercise therapy was introduced during the period of hospital admission. To observe the effect of dietary therapy on the plasma glucose level, in principle, we continued the diabetes therapy that was being received at admission for at least 3 days after admission, except among participants with extremely high plasma glucose levels. In participants who were treated with more than half the maximum dose of sulfonylureas (SU), if the optimal glycemic goal according to the JDS guidelines[20](#jdi12181-bib-0020){ref-type="ref"} (FPG \< 130 mg/dL or 2‐h postprandial plasma glucose \<180 mg/dL) was not achieved within 1 week after admission, intensive insulin therapy was, in principle, started and SU treatment was discontinued. In the remaining participants, if the optimal glycemic goal was not achieved within 1 week after admission, the SU or other OHA dosage was started or increased. Nevertheless, if the optimal glycemic goal was not achieved, intensive insulin therapy was considered. According to our treatment policies for the medications indicated here, to achieve an optimal glycemic goal, we modified the diabetes therapy of the study participants during their admission. Among the participants who had received intensive insulin therapy, if the optimal glycemic control was maintained at a dosage of \<10 U/day of insulin, we discontinued insulin therapy and started treatment with sulfonylurea and/or another OHA; if the aforementioned criterion was not met, the participants were judged as requiring insulin therapy and insulin therapy was continued during admission. As a result, 47.8% of the participants were receiving insulin therapy at the time of hospital discharge (Table [1](#jdi12181-tbl-0001){ref-type="table-wrap"}). After hospital discharge, lifestyle modification was also recommended at the time of periodical outpatient visits. Based on the treatment that was being carried out at 12 months after hospital discharge, we divided the 188 patients into an insulin‐requiring group and a non‐insulin‐requiring group as follows: a)Insulin‐requiring group (IR): Participants who were required to inject more than 10 U of insulin a day continuously were regarded as belonging to the insulin‐requiring group as previously reported[10](#jdi12181-bib-0010 jdi12181-bib-0013){ref-type="ref"}.b)Non‐insulin‐requiring group (NIR): Participants who were treated with diet alone or OHA, but not with insulin treatment, and had HbA1c levels \< 7.0% at 12 months after discharge were regarded as belonging to the non‐insulin‐requiring group.

![Classification of study participants. Based on the treatment that was being carried out at 12 months after hospital discharge, we divided the 188 patients into an insulin‐requiring group and a non‐insulin‐requiring group as follows. (a) Insulin‐requiring group (IR). Patients who were required to inject more than 10 U of insulin a day continuously were regarded as belonging to the insulin‐requiring group. (b) Non‐insulin‐requiring group (NIR). Patients who were treated with diet alone or oral hypoglycemic agents (OHA), but not with insulin treatment, and had glycosylated hemoglobin A1c (HbA1c) levels \< 7.0% at 12 months after discharge were regarded as belonging to the non‐insulin‐requiring group. \*Other reasons: we excluded: (i) patients with a serum creatinine level of 1.5 mg/dL or more; (ii) patients with hepatic dysfunction or malignant disease, or who were taking steroids; and (iii) patients who could not be clinically followed for at least 12 months.](jdi-5-570-g1){#jdi12181-fig-0001}

Statistical Analysis {#jdi12181-sec-0010}
--------------------

All the data were expressed as the mean ± standard deviation. The statistical analyses were carried out using JMP for Windows, Version 8.0 (SAS Institute, Cary, NC, USA). Differences in the clinical features of the NIR and IR subgroups were examined using the Mann--Whitney *U*‐test and multiple regression analysis after adjustments for related covariables. The relationships between parameters of β‐cell function were investigated using simple and partial regression analysis. A receiver operating characteristic (ROC) curve analysis was carried out to compare the power of several β‐cell function‐related parameters for predicting the requirement for insulin therapy using the method described previously[21](#jdi12181-bib-0021){ref-type="ref"}. We carried out a univariate logistic regression analysis and multivariate logistic analysis to evaluate the effect of several β‐cell function and other parameters at admission on the insulin requirement at 1 year after discharge. Results with *P*‐values \< 0.05 were considered statistically significant.

Results {#jdi12181-sec-0011}
=======

Correlations Among the β‐Cell Function‐Related Parameters {#jdi12181-sec-0012}
---------------------------------------------------------

The F‐CPR, CPI, and SUIT values were all significantly and positively correlated with the HOMA‐β (*P *\< 0.05; Table [2](#jdi12181-tbl-0002){ref-type="table-wrap"}). However, the correlation coefficient with HOMA‐β was the greatest for SUIT (*r *= 0.973, *P *\< 0.0001), followed by CPI and then F‐CPR (Figure [2](#jdi12181-fig-0002){ref-type="fig"}, Table [2](#jdi12181-tbl-0002){ref-type="table-wrap"}). The U‐CPR and U‐CPR index showed a nominal association with each serum parameter of β‐cell function (*P* \< 0.05), except for the SUIT and HOMA‐β (Table [2](#jdi12181-tbl-0002){ref-type="table-wrap"}).

###### Correlations between C‐peptide‐based indices and insulin‐based indices

                                                                       F‐CPR   CPI     SUIT    F‐IRI   HOMA‐β   U‐CPR      U‐CPR index
  -------------------------------------------------------------------- ------- ------- ------- ------- -------- ---------- -------------
  Simple correlations coefficients among markers of β‐cell function                                                        
  F‐CPR                                                                --      0.788   0.377   0.825   0.401    0.196      0.192
  CPI                                                                          --      0.73    0.706   0.733    0.151      0.288
  SUIT                                                                                 --      0.303   0.973    *−0.01*    *0.112*
  F‐IRI                                                                                        --      0.434    0.281      0.264
  HOMA‐β                                                                                               --       *0.023*    *0.125*
  U‐CPR                                                                                                         --         0.879
  UCPRI                                                                                                                    --
  Partial correlations coefficients among markers of β‐cell function                                                       
  F‐CPR                                                                --      0.749   0.265   0.802   0.431    0.196      0.134
  CPI                                                                          --      0.686   0.665   0.829    0.145      0.224
  SUIT                                                                                 --      0.373   0.974    *−0.064*   *0.025*
  F‐IRI                                                                                        --      0.485    0.195      *0.116*
  HOMA‐β                                                                                               --       *−0.035*   *0.035*
  U‐CPR                                                                                                         --         0.871
  U‐CPR index                                                                                                              --

The partial correlation analysis was carried out using independent variables such as age, sex, glycosylated hemoglobin A1c level, body mass index, estimated glomerular filtration rate, intake of insulin secretagogue, intake of α‐glucosidase inhibitor, intake of biguanides and duration of diabetes. A value of *P* \< 0.05 was obtained for all the comparisons except for the correlation coefficients presented in italics. CPI, C‐peptide index; F‐CPR, fasting serum C‐peptide immunoreactivity; F‐IRI, fasting immunoreactive insulin; FPG, fasting plasma glucose; HOMA‐β, homeostasis model assessment of β‐cell function; SUIT, secretory units of islets in transplantation index; U‐CPR, 24‐h urinary C‐peptide; U‐CPR index, 24‐h urinary C‐peptide/fasting plasma glucose.
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![Correlation between secretory units of islets in transplantation index (SUIT) and homeostasis model assessment of β‐cell function (HOMA‐β).](jdi-5-570-g2){#jdi12181-fig-0002}

Comparison of the Clinical Characteristics and β‐Cell Function‐Related Parameters at Admission Between the Insulin‐Requiring Group and the Non‐Insulin‐Requiring Group {#jdi12181-sec-0013}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Among the 188 participants, 76 participants (40.4%) were receiving insulin treatment at 12 months after discharge (Table [1](#jdi12181-tbl-0001){ref-type="table-wrap"}). Among the patients in the IR group, the mean daily insulin dose was 0.32 ± 0.18 U/kg (19 ± 8 U; range 10--52 U; Table [1](#jdi12181-tbl-0001){ref-type="table-wrap"}). The HbA1c levels in the IR and NIR groups at 12 months after discharge were 7.88% and 6.66% (*P *\< 0.001), respectively (Table [1](#jdi12181-tbl-0001){ref-type="table-wrap"}).

The clinical characteristics for the two groups at admission are summarized in Table [1](#jdi12181-tbl-0001){ref-type="table-wrap"}. The patients in the IR group had a significantly longer duration of diabetes (*P *\< 0.01), a higher percentage of a family history of diabetes mellitus (*P *\< 0.05) and a higher HbA1c level (*P *\< 0.001) at the time of admission, compared with those in the NIR. The percentage of individuals who had received an oral insulin secretagogue before admission and the incidence of diabetic complications, except for diabetic nephropathy, were also significantly higher in the patients in the IR group than in those in the NIR group (*P *\< 0.01 and *P *\< 0.05, respectively). The CPI, SUIT and HOMA‐β were significantly lower in the patients in the IR group than in those in the NIR group (*P *\< 0.01), even after adjustments for confounding factors (Table [1](#jdi12181-tbl-0001){ref-type="table-wrap"}).

Predictive Ability of the β‐Cell Function‐Related Parameters at Admission {#jdi12181-sec-0014}
-------------------------------------------------------------------------

To estimate the abilities of these β‐cell function‐related parameters to predict insulin requirement, we carried out a ROC analysis. The ROC analysis for insulin requirement showed that the area under the curve (AUC) for SUIT (0.808; 95% CI 0. 751--0.865) was significantly larger than those for other parameters of β‐cell function, except for the AUC for CPI and that for HOMA‐β (Table [3](#jdi12181-tbl-0003){ref-type="table-wrap"}). After SUIT, the CPI and HOMA‐β had significantly greater AUC values (AUC for CPI 0.774; 95% CI 0.713--0.834; AUC for HOMA‐β 0.759; 95% CI 0.694--0.826) for insulin requirement than the F‐CPR itself and U‐CPR (*P* \< 0.05; Table [3](#jdi12181-tbl-0003){ref-type="table-wrap"}). Setting a cut‐off level to obtain a high specificity of at least 80% for insulin requirement, the cut‐off values for SUIT, CPI, and HOMA‐β were 23.5 (66.7% sensitivity), 1.00 (61.3% sensitivity), and 14.9 (61.7% sensitivity), respectively (Table [3](#jdi12181-tbl-0003){ref-type="table-wrap"}). To examine the effect of FPG or BMI at admission on the cut‐off values and the predictive ability of each index for predicting insulin requirement, we divided the 188 participants into three approximately equally sized strata according to the FPG or BMI at admission (Table [4](#jdi12181-tbl-0004){ref-type="table-wrap"}). The cut‐off values for SUIT, CPI and HOMA‐β with an over 80% specificity for predicting insulin requirement in the high FPG group were lower than those in the low FPG group. Furthermore, the cut‐off values for these indices with an over 80% specificity for predicting insulin requirement in the high BMI group were higher than those in the low BMI group. The AUC values of the ROC analysis for predicting insulin requirement were not significantly different among SUIT, CPI and HOMA‐β in each stratum. The AUC of the ROC analysis for predicting insulin requirement of CPI and SUIT tended to be lower in the high FPG group than in the low FPG group, whereas those of all three indices were comparable in the three groups divided according to the BMI at admission.

###### Area under the curve of the receiver operating characteristic analysis for the prediction of insulin requirement or non‐insulin requirement among β‐cell function‐related parameters

                Requirement/non‐requirement for insulin therapy   Insulin requirement   Non‐insulin requirement                                      
  ------------- ------------------------------------------------- --------------------- ------------------------- ------ ------ ------ ------ ------ ------
  F‐CPR         0.622 (0.552--0.693)                              \<0.05                1.50                      37.3   1.40   36.0   87.0   2.70   22.2
  CPI           0.774 (0.713--0.834)                              NS                    1.00                      61.3   1.14   73.3   71.7   1.42   58.3
  SUIT          0.808 (0.751--0.865)                              --                    23.5                      66.7   29.7   78.7   74.1   30.6   71.3
  HOMA‐β        0.759 (0.694--0.826)                              NS                    14.9                      61.7   14.9   61.7   80.4   24.3   57.7
  U‐CPR         0.603 (0.529--0.676)                              \<0.05                22.2                      32.9   61.0   80.0   40.0   63.0   40.0
  U‐CPR index   0.668 (0.596--0.740)                              \<0.05                0.15                      40.0   0.34   77.1   52.1   0.38   47.9

AUC, area under receiver operator characteristics curve; CPI, C‐peptide index; F‐CPR, fasting serum C‐peptide immunoreactivity; HOMA‐β, homeostasis model assessment of β‐cell function; NS, no significant difference; SUIT, secretory units of islets in transplantation index; U‐CPR, 24‐h urinary C‐peptide; U‐CPR index, 24‐h urinary C‐peptide/fasting plasma glucose.
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###### Effect of fasting plasma glucose and body mass index at admission on the cut‐off values, and the ability of the C‐peptide index, secretory units of islets in transplantation index, and homeostasis model assessment of β‐cell function to predict insulin requirement according to receiver operating characteristic analysis

  Classification of three groups according to FPG at admission                                                                  
  ---------------------------------------------------------------------------------- -------------- ------------- ------------- --------------
  *n* (Male/female)                                                                  188 (126/62)   62 (39/23)    62 (37/25)    63 (50/13)
  Age (years)                                                                        61.0 ± 12.6    62.6 ± 12.2   61.1 ± 12.1   59.4 ± 13.4
  FPG                                                                                176.1 ± 71.1   113 ± 14.5    160 ± 16.8    254.1 ± 65.4
  BMI                                                                                24.6 ± 4.8     25.6 ± 5.7    24.6 ± 4.7    23.7 ± 3.8
  Insulin requirement (%)                                                            40.6           9.7           43.6          68.3
  Cut‐off value for over 80% specificity for the prediction of insulin requirement                                              
  CPI                                                                                1.00           1.29          1.08          0.69
  SUIT                                                                               23.5           41.7          25.3          12.9
  HOMA‐β                                                                             14.9           23.1          14.9          7.4
  AUC of the ROC analysis for the prediction of insulin requirement                                                             
  CPI                                                                                0.774          0.687         0.661         0.575
  SUIT                                                                               0.808          0.704         0.684         0.601
  HOMA‐β                                                                             0.759          0.548         0.675         0.628

  Classification of three groups according to BMI at admission                                                     
  ------------------------------------------------------------------- -------------- -------------- -------------- --------------
  No. (M/F)                                                           188 (126/62)   63 (45/18)     66 (45/21)     59 (36/23)
  Age (years)                                                         61.0 ± 12.6    63.0 ± 9.7     64.3 ± 12.1    55.4 ± 14.1
  FPG                                                                 176.1 ± 71.1   186.6 ± 82.4   173.3 ± 57.1   167.9 ± 72.2
  BMI                                                                 24.6 ± 4.8     20.3 ± 1.9     24.5 ± 0.9     29.4 ± 5.1
  Insulin requirement (%)                                             40.6           54.0           37.9           28.8
  Cut‐off value for over 80% specificity for insulin requirement                                                   
  CPI                                                                 1.00           0.79           1.02           1.11
  SUIT                                                                23.5           19.3           29.7           28.6
  HOMA‐β                                                              14.9           8.7            13.8           21.2
  AUC of the ROC analysis for the prediction of insulin requirement                                                
  CPI                                                                 0.774          0.736          0.732          0.764
  SUIT                                                                0.808          0.773          0.793          0.788
  HOMA‐β                                                              0.759          0.759          0.734          0.768

Data are the mean ± standard deviation. AUC, area under receiver‐operator characteristics curve; BMI, body mass index; CPI, C‐peptide index; FPG, fasting plasma glucose; HOMA‐β, homeostasis model assessment of β‐cell function; ROC, receiver operating characteristic; SUIT, secretory units of islets in transplantation index.
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Association of the β‐Cell Function‐Related Parameters and Other Clinical Parameters at Admission with Insulin Requirement {#jdi12181-sec-0015}
-------------------------------------------------------------------------------------------------------------------------

Finally, to evaluate the effect of several β‐cell function and other parameters at admission on the insulin requirement, we carried out univariate logistic regression analyses (Table [5](#jdi12181-tbl-0005){ref-type="table-wrap"}). Then, we incorporated the variables that were significantly related to IR as explanatory variables in a multivariate logistic analysis (Table [6](#jdi12181-tbl-0006){ref-type="table-wrap"}). As a result, pretreatment with sulfonylurea and the HbA1c level at admission were identified as independent predictors of insulin requirement in all the models in addition to CPI, SUIT, and HOMA‐β (Table [6](#jdi12181-tbl-0006){ref-type="table-wrap"}). In addition, the ROC analysis for insulin requirement also showed that the AUC for HbA1c level at admission (0.723; 95% CI 0.659--0.787) was comparable with that for HOMA‐β (Table S1).

###### Univariate logistic regression analysis for the prediction of insulin requirement

  Variables                                                          Odds ratio (95% CI)   *P*‐value
  ------------------------------------------------------------------ --------------------- -----------
  Age (years)                                                        0.99 (0.97--1.02)     0.488
  Sex (male = 1, Female = 0)                                         1.01 (0.54--1.88)     0.983
  Duration of diabetes (years)                                       1.06 (1.02--1.11)     \<0.01
  Family history of diabetes (yes = 1, no = 0)                       1.88 (1.04--3.43)     \<0.05
  BMI                                                                0.91 (0.84--0.98)     \<0.05
  HbA1c at admission                                                 1.41 (1.22--1.64)     \<0.001
  eGFR                                                               1.00 (0.99--1.02)     0.451
  Intake of sulfonylurea at admission (yes = 1, no = 0)              2.22 (1.23--4.06)     \<0.01
  Intake of α‐glucosidase inhibitor at admission (yes = 1, no = 0)   1.83 (1.15--3.85)     \<0.01
  Intake of biguanides at admission (yes = 1, no = 0)                1.63 (1.05--3.57)     \<0.05
  Diabetic retinopathy (yes = 1, no = 0)                             3.50 (1.83--6.83)     \<0.001
  Diabetic nephropathy (yes = 1, no = 0)                             1.02 (0.53--1.93)     0.959
  Diabetic neuropathy (yes = 1, no = 0)                              2.09 (1.12--3.92)     \<0.05
  F‐CPR (ng/mL)                                                      0.72 (0.52--0.99)     \<0.05
  CPI                                                                0.25 (0.14--0.42)     \<0.001
  SUIT                                                               0.95 (0.93--0.97)     \<0.001
  HOMA‐IR                                                            1.00 (0.85--1.18)     0.953
  HOMA‐β (%)                                                         0.96 (0.94--0.98)     \<0.001
  U‐CPR (μg/day)                                                     0.99 (0.98--1.00)     0.069
  U‐CPR index                                                        0.12 (0.03--0.40)     \<0.001

CI, confidence interval; CPI, C‐peptide index; eGFR, estimated glomerular filtration rate; F‐CPR, fasting serum C‐peptide immunoreactivity; HOMA‐β, homeostasis model assessment of β‐cell function; HOMA‐IR, homeostasis model assessment of insulin resistance; SUIT, secretory units of islets in transplantation index; U‐CPR, 24‐h urinary C‐peptide; U‐CPR index, 24‐h urinary C‐peptide/fasting plasma glucose.
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###### Multivariate logistic regression analysis for the prediction of insulin requirement

  Variables                                               Model 1             Model 2   Model 3                                          
  ------------------------------------------------------- ------------------- --------- ------------------- -------- ------------------- ---------
  Duration of diabetes (years)                            1.02 (0.96--1.09)   0.473     1.03 (0.97--1.10)   0.343    1.02 (0.95--1.09)   0.582
  Family history of diabetes (yes = 1, no = 0)            1.63 (0.76--3.55)   0.211     2.62 (1.16--6.11)   \<0.05   1.80 (0.82--3.99)   0.143
  BMI                                                     0.99 (0.89--1.09)   0.800     1.00 (0.89--1.11)   0.943    0.99 (0.90--1.09)   0.873
  HbA1c at admission                                      1.28 (1.05--1.59)   \<0.05    1.30 (1.05--1.65)   \<0.05   1.23 (1.01--1.48)   \<0.05
  Intake of sulfonylurea at admission (yes = 1, no = 0)   3.77 (1.63--9.35)   \<0.01    3.25 (1.37--8.13)   \<0.01   3.77 (1.60--9.46)   \<0.01
  Intake of α‐GI at admission (yes = 1, no = 0)           2.09 (0.79--5.74)   0.139     2.00 (0.69--6.01)   0.202    2.14 (0.79--6.01)   0.134
  Intake of biguanides at admission (yes = 1, no = 0)     1.69 (0.48--6.17)   0.409     1.38 (0.32--6.00)   0.662    1.73 (0.45--7.10)   0.426
  Diabetic retinopathy (yes = 1, no = 0)                  2.69 (1.06--7.09)   \<0.05    2.26 (0.87--6.00)   0.095    2.98 (1.12--8.31)   \<0.05
  Diabetic neuropathy (yes = 1, no = 0)                   1.97 (0.86--4.57)   0.108     1.83 (0.76--4.43)   0.175    1.80 (0.82--3.99)   0.099
  CPI                                                     0.26 (0.12--0.53)   \<0.001   --                           --                  --
  HOMA‐β                                                  --                  --        0.97 (0.94--0.99)   \<0.01   --                  --
  SUIT                                                    --                  --        --                           0.95 (0.92--0.97)   \<0.001

Multivariate logistic regression analyses were carried out in models 1--3. Model 1 was adjusted for duration of diabetes, family history of diabetes, body mass index (BMI), glycosylated hemoglobin A1c (HbA1c) at admission, intake of insulin secretagogue, intake of α‐glucosidase inhibitor (α‐GI), intake of biguanides, presence of diabetic complications (diabetic retinopathy and diabetic neuropathy) and C‐peptide index (CPI). Model 2 was adjusted for all the variables included in model 1 except for CPI and with the addition of homeostasis model assessment of β‐cell function (HOMA‐β). Model 3 was adjusted for all the variables included in model 1 except for CPI and with the addition of secretory units of islets in transplantation index (SUIT). CI, confidence interval.
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Discussion {#jdi12181-sec-0016}
==========

In the present study, it was found that: (i) the correlation with HOMA‐β was the greatest for SUIT, followed by CPI and the least for F‐CPR; (ii) patients who required insulin therapy had a lower SUIT, CPI and HOMA‐β at the time of admission, even after adjustments for confounding factors; (iii) among the β‐cell function‐related parameters, SUIT had the greatest AUC in the ROC analysis for predicting insulin requirement, followed by CPI and HOMA‐β; and (iv) the cut‐off values for SUIT, CPI, and HOMA‐β with an over 80% specificity for the prediction of insulin requirement were affected by FPG and BMI at admission.

One of the most important points in the present study was the strict selection of patients who belonged to the non‐insulin‐requiring group (NIR). To validate the patients who did not require insulin therapy, we selected patients who achieved a glycemic control of HbA1c \< 7.0% with diet alone or OHA, but not with insulin treatment, at 1 year after discharge; these patients were considered to belong to the NIR group. Without these criteria, patients who failed to achieve good blood glucose control without insulin therapy, either partly because of their rejection of insulin therapy or because of mistakes in their treatment made by diabetologists, would have been included in the NIR group; as a result, the cut‐off level and the predictive ability of β‐cell‐related parameters for insulin requirement might not have been accurately determined. Several reports examining the correlation between the levels of endogenous insulin secretion and the insulin requirement have been carried out in Japanese diabetic patients[10](#jdi12181-bib-0010 jdi12181-bib-0013 jdi12181-bib-0014 jdi12181-bib-0016){ref-type="ref"}. However, in these reports, the glycemic goal was not described clearly[10](#jdi12181-bib-0010){ref-type="ref"}, and patients with insufficient glycemic control with OHA were sometimes included in the NIR group[13](#jdi12181-bib-0013 jdi12181-bib-0016){ref-type="ref"}, except in one recent study[14](#jdi12181-bib-0014){ref-type="ref"}. Furthermore, in that study[14](#jdi12181-bib-0014){ref-type="ref"}, they observed the relationship between glycemic control and diabetes treatment in participants only during the period of hospitalization. We believe that this observation period is too short to judge whether insulin therapy is required, as most patients are unable to maintain good glycemic control after discharge because of inappropriate lifestyle behaviors. Therefore, the present study is the first report to examine the predictive ability and the cut‐off level of β‐cell function‐related parameters for insulin requirement using strict inclusion criteria for the NIR group and with a sufficient observation period. Regarding the selection of the participants belonging to the insulin‐requiring group (IR), we selected these participants for the following reasons. In the study examining the clinical parameters for predicting the possibility of insulin therapy withdrawal carried out in Japanese patients with type 2 diabetes mellitus, it has been reported that the patients, who had been treated with an insulin dose \<14 U/day, were able to be withdrawn from insulin therapy after receiving intensive therapy[22](#jdi12181-bib-0022){ref-type="ref"}. In addition, we quoted the criterion of the IR group as previously reported[10](#jdi12181-bib-0010 jdi12181-bib-0013){ref-type="ref"}; as a result, we defined the participants who were required to inject more than 10 U of insulin a day continuously as the IR group.

Also importantly, the present study is the first to compare not only C‐peptide‐based indices (either serum or urinary), but also HOMA‐β, which is widely used for assessing the insulin secretory capacity[3](#jdi12181-bib-0003){ref-type="ref"}. Previous reports compared only C‐peptide‐based indices[9](#jdi12181-bib-0009 jdi12181-bib-0010 jdi12181-bib-0011 jdi12181-bib-0013 jdi12181-bib-0014 jdi12181-bib-0015 jdi12181-bib-0016){ref-type="ref"}. Although Taverna *et al*.[12](#jdi12181-bib-0012){ref-type="ref"} reported that HOMA‐β was a good predictor of the insulin‐requiring stage in type 2 diabetes, they did not compare the abilities of HOMA‐β and other β‐cell function‐related indices to predict insulin requirement[12](#jdi12181-bib-0012){ref-type="ref"}. Here, we showed for the first time that among the C‐peptide‐based indices and HOMA‐β, SUIT had the best ability to predict insulin requirement, and that the CPI was comparable with HOMA‐β in its predictive ability.

SUIT was developed using F‐CPR and the FPG level after islet transplantation, and reported to be correlated with the glucagon stimulated C‐peptide levels not only in islet‐transplanted patients, but also in type 2 patients[8](#jdi12181-bib-0008){ref-type="ref"}. This index was originally developed on the assumption that when the FPG falls to 61.7 mg/dL, endogenous insulin secretion reaches zero. In contrast, in the case of the CPI, when the FPG reaches zero, the serum C‐peptide is assumed to be zero, which does not reflect the physiological situation. Therefore, we speculated that as the formula for SUIT reflected the physiological endogenous insulin secretion more closely than the formula for CPI, SUIT might be a better predictor of the insulin requirement, compared with CPI, in the present study. SUIT resembles HOMA‐β in that its formula assumes that insulin secretion is suppressed to zero at approximately 60 mg/dL of glucose; in the present study, we showed that SUIT was more strongly correlated with HOMA‐β (*r* = 0.973, *P *\< 0.0001; Figure [2](#jdi12181-fig-0002){ref-type="fig"}, Table [2](#jdi12181-tbl-0002){ref-type="table-wrap"}) than with other β ‐cell function‐related parameters. However, HOMA‐β had a lower ability to predict insulin requirement than SUIT. We speculated that this finding might have reflected metabolic differences between serum C‐peptide and insulin; specifically, C‐peptide is split from insulin in the secretory granules of β ‐cells and is co‐secreted with insulin; then insulin, but not C‐peptide, is extracted by the liver[23](#jdi12181-bib-0023){ref-type="ref"}.

We also examined the effect of FPG or BMI at admission on the cut‐off value for the prediction of insulin requirement. The cut‐off values of SUIT, CPI, and HOMA‐β for an over 80% specificity for the prediction of insulin requirement were lower in the high FPG group and higher in the high BMI group. A higher FPG at admission might have impaired endogenous insulin secretion because of the glucose toxicity effect, resulting in lower values for each parameter. It is also possible that as a higher BMI is associated with insulin resistance, the cut‐off values for the prediction of insulin requirement were higher to compensate for the increased demand of insulin to control blood glucose levels. These findings show that the cut‐off value for the prediction of insulin requirement was affected by the FPG and BMI at admission.

The present study had several limitations. First, this study was a retrospective analysis of inpatients at one hospital. Second, we also included patients whose FPG was 200 mg/dL or more, although the HOMA‐β was reported to be valid within 234 mg/dL of FPG[7](#jdi12181-bib-0007){ref-type="ref"}. We also excluded 34 patients whose FPG was 234 mg/dL or more and re‐analyzed the predictive ability of the β ‐cell function‐related parameters in 154 patients with type 2 diabetes. However, we obtained results that were similar (CPI, AUC = 0.729; SUIT, AUC = 0.771; HOMA‐β, AUC = 0.693) to those obtained in participants including whose FPG was 234 mg/dL or more. Third, we did not measure the plasma glucagon‐stimulated C‐peptide level or the postprandial C‐peptide to glucose ratio (PGCR). The former is well known as a gold standard test to evaluate β‐cell function[24](#jdi12181-bib-0024){ref-type="ref"}, whereas the latter was recently reported to be a better predictor of insulin requirement than the fasting CPI[10](#jdi12181-bib-0010 jdi12181-bib-0025){ref-type="ref"}. Unfortunately, as we did not measure these parameters, we were unable to compare the usefulness of these indices with those of fasting CPI, SUIT and HOMA‐β. Fourth, among the 442 patients with type 2 diabetes who were admitted to our hospital during a period of approximately 5 years, to compare the ability of HOMA‐β and the C peptide‐related index to predict insulin requirement, and to recruit patients according to the strict inclusion criteria for insulin requirement, we excluded many patients from the present study (Figure [1](#jdi12181-fig-0001){ref-type="fig"}). The patients who were excluded from this study had a longer duration of diabetes, and a lower insulin secretion than those who were included in this study (Table S2). Therefore, these selection biases might have slightly affected our conclusion. Fifth, we did not fully examine the changes in treatment during the follow‐up period after discharge. In the present study, during the 1‐year period after hospital discharge, 15.2% of the participants in the NIR group stopped receiving insulin therapy, and 3.9% of the participants in the IR group started receiving insulin therapy. Therefore, these changes in diabetes treatment after hospital discharge might have slightly affected the conclusion of this study. Sixth, incretin therapy, such as the use of dipeptidyl peptidase 4 (DPP‐4) inhibitor, has recently been frequently used in the treatment of type 2 diabetes. However, in the present study, only a small proportion (1.3%) of the participants were treated with DPP‐4 inhibitor. The addition of DPP‐4 inhibitor has been reported to decrease the HbA1c level effectively in patients with insufficient glycemic control despite the use of SU, probably because DPP‐4 inhibitor and SU are thought to stimulate insulin secretion in a coordinated and synergistic manner[26](#jdi12181-bib-0026 jdi12181-bib-0027){ref-type="ref"}. Therefore, if the patients treated with DPP‐4 inhibitor became a larger proportion of the study participants, the cut off value of β‐cell function‐related parameters for insulin requirement might change. Seventh, the number of events per variable was \<10 in the multivariate logistic regression analysis (Table [6](#jdi12181-tbl-0006){ref-type="table-wrap"}), so the results should be interpreted with caution[28](#jdi12181-bib-0028){ref-type="ref"}.

In conclusion, among the indices of β‐cell function examined in the present study, SUIT was the best predictive marker of insulin requirement. However, this study was carried out retrospectively. A prospective study involving a larger number of participants is required to clarify the present findings.
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**Table S1 \|** Area under the curve of the receiver operating characteristic analysis for the prediction of insulin requirement of fasting plasma glucose, glycosylated hemoglobin A1c, body mass index and homeostasis model assessment of insulin resistance at admission.

**Table S2 \|** Comparison of clinical characteristics between patients who were included in this study and those who were excluded.
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